PIGMENTED VILLONODULAR SYNOVITIS
Clinical trials for PIGMENTED VILLONODULAR SYNOVITIS explained in plain language.
Never miss a new study
Get alerted when new PIGMENTED VILLONODULAR SYNOVITIS trials appear
Sign up with your email to follow new studies for PIGMENTED VILLONODULAR SYNOVITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare joint tumor in early trial
Disease control OngoingThis study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill shows promise for rare joint tumor in Late-Stage trial
Disease control OngoingThis Phase 3 trial tests whether the drug Pimicotinib (ABSK021) can shrink tumors and improve symptoms in people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that cannot be surgically removed. About 94 adults will receive either the drug or a …
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC